Hospital
CPH Hospital Management LLC
CPH Hospital Management LLC was paid $3.68M by Medicaid between Jan 2018 and Dec 2024, across 108 billing codes. Its largest line is 0450, Emergency room services — 31% of everything it billed.
33Billing provider infoCPH HOSPITAL MANAGEMENT LLC
NORWALK, CA 90650
NORWALK, CA 90650
33aNPI1194016923assigned 04/27/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.68M
24GClaims195,327
24DCodes billed108
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#239 of 410
Median peer was paid$6.90M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,083 | $675K | |
| 2019 | 31,731 | $689K | |
| 2020 | 20,982 | $377K | |
| 2021 | 20,303 | $394K | |
| 2022 | 25,006 | $509K | |
| 2023 | 31,098 | $612K | |
| 2024incomplete | 24,124 | $420K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 31% | 28,925 | 26,429 | $1.13M |
| 70450 | Computed tomography, head or brain; without contrast material | 7.6% | 3,320 | 3,193 | $278K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.5% | 2,646 | 2,543 | $237K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.3% | 5,420 | 4,987 | $195K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.2% | 3,552 | 3,360 | $155K |
| Z7502 | 3.3% | 3,300 | 3,175 | $121K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.0% | 2,399 | 2,066 | $109K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 5,241 | 4,915 | $90K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.3% | 4,110 | 3,884 | $84K |
| 80053 | Comprehensive metabolic panel | 2.2% | 10,366 | 9,676 | $81K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 3,346 | 3,157 | $79K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 365 | 357 | $73K |
96 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 2.0% | 2,566 | $73K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.7% | 1,382 | $62K |
| 99199 | Unlisted special service, procedure or report | 1.6% | 1,573 | $60K |
| 99284 | Emergency room visit (serious) | 1.6% | 927 | $57K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 10,541 | $55K |
| 94642 | 1.4% | 622 | $52K | |
| J3490 | Unclassified drugs | 1.4% | 11,656 | $51K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 4,882 | $51K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 955 | $50K |
| 0270 | 1.2% | 17,055 | $44K | |
| 99283 | Emergency room visit (moderate) | 1.0% | 653 | $37K |
| Z7610 | <1% | 2,441 | $32K | |
| 72131 | <1% | 257 | $26K | |
| 0636 | <1% | 2,280 | $26K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 882 | $23K |
| 0250 | <1% | 4,349 | $22K | |
| 84484 | <1% | 3,416 | $22K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 183 | $22K |
| 0272 | <1% | 3,501 | $19K | |
| 81025 | <1% | 5,143 | $19K | |
| 0360 | <1% | 270 | $17K | |
| 83880 | <1% | 1,030 | $17K | |
| 83690 | <1% | 3,240 | $16K | |
| 85730 | <1% | 3,867 | $15K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,771 | $14K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 947 | $14K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,265 | $13K |
| 81001 | <1% | 5,055 | $12K | |
| 87040 | <1% | 926 | $10K | |
| 85610 | <1% | 4,011 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,095 | $7K |
| 0710 | <1% | 666 | $7K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 185 | $6K |
| 83605 | <1% | 715 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 748 | $5K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 327 | $5K |
| 87077 | <1% | 951 | $5K | |
| 90715 | <1% | 166 | $5K | |
| 81003 | <1% | 2,947 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $4K |
| 87186 | <1% | 678 | $4K | |
| 80320 | <1% | 1,827 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 60 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 674 | $4K |
| 82948 | <1% | 1,247 | $3K | |
| 84703 | <1% | 502 | $2K | |
| 70486 | <1% | 24 | $2K | |
| 73130 | <1% | 117 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 519 | $2K |
| 86328 | <1% | 72 | $2K | |
| 85007 | <1% | 691 | $1K | |
| 94760 | <1% | 217 | $1K | |
| 86769 | <1% | 79 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 369 | $1K |
| 80329 | <1% | 317 | $1K | |
| 85027 | <1% | 279 | $1K | |
| 73630 | <1% | 49 | $868.04 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 85 | $813.66 |
| A0429 | Emergency ambulance ride, basic life support | <1% | 20 | $813.21 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 147 | $807.90 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15 | $795.18 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,973 | $699.52 |
| 82553 | <1% | 101 | $639.43 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 72 | $629.96 |
| 96368 | <1% | 40 | $614.98 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $612.51 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 57 | $604.69 |
| 99070 | <1% | 167 | $594.73 | |
| 87807 | <1% | 104 | $524.46 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 153 | $500.25 |
| A4649 | Surgical supply; miscellaneous | <1% | 773 | $496.71 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 101 | $404.92 |
| 73562 | <1% | 26 | $399.61 | |
| 80354 | <1% | 673 | $396.51 | |
| 73110 | <1% | 12 | $347.72 | |
| 82150 | <1% | 46 | $205.41 | |
| 0324 | <1% | 29 | $201.61 | |
| 83735 | <1% | 40 | $156.29 | |
| 85014 | <1% | 47 | $148.01 | |
| 73610 | <1% | 13 | $141.81 | |
| 85018 | <1% | 56 | $139.72 | |
| 87400 | <1% | 51 | $126.66 | |
| 88313 | <1% | 13 | $115.66 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 30 | $112.15 |
| 88312 | <1% | 13 | $98.49 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 12 | $73.19 |
| 84512 | <1% | 13 | $63.46 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 77 | $53.14 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12 | $46.16 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13 | $42.90 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14 | $36.76 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 72 | $13.90 |
| A6446 | Conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to three inches and less than five inches, per yard | <1% | 12 | $0.70 |
| 0301 | 0% | 13 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 36 | $0.00 |
| 0300 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMACPHERSON, JAMES (MANAGER)
| Provider | Location | Paid |
|---|---|---|
| CHHP Holdings II, LLC | Huntington Park, CA | $17.21M |
| Gardena Hospital LP | Gardena, CA | $15.36M |
| Eladh, LP | Los Angeles, CA | $5.38M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.